A Phase 4 interventional study of finerenone in Primary Aldosteronism, sponsored by Chongqing Medical University. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-06-18.
Sponsored by Chongqing Medical University · Phase 4, Interventional, and Treatment
To study the efficacy and safety of finerenone in patients with primary aldosteronism
This is a prospective and randomized study involving patients with primary aldosteronism(PA). All paticipants will be randomized into finerenone group(Intervention group) and spironolactone group(Control group) and to compare the antihypertensive effect in patients with PA.
If the self-measured blood pressure of patients at home continues to be greater than 140/90 mmHg at 2-4 weeks, spironolactone or finerenone should be increased to 40mg qd, and electrolytes should be reviewed at 2 weeks after dosed.
193 studies on the registry are indexed under Hyperaldosteronism; 89 are open to participants now.
This study's enrollment of 60 is close to the median of 60 across 91 interventional studies indexed under Hyperaldosteronism.
Browse Hyperaldosteronism studies →Chongqing Medical University is the lead sponsor of 75 studies on the registry; 17 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria: Patients who meet the following criterion can be included in this study.
Exclusion Criteria: Patients with one of the following conditions will be excluded in this study:
Patients with PA divided into this group need to take finerenone for 60 days (20mg qd)
Drug: finerenone
Patients with PA divided into this group need to take spironolactone for 60 days (20mg qd)
Patients with PA divided into Intervention group need to take finerenone for 60 days (20mg qd).
Also known as: Kerendia
Compare the change of daytime mean systolic blood pressure in the overall cohort between two groups.
Measured by ambulatory blood pressure monitoring
Time frame: At baseline and 2 month of follow-up
Compare the serum potassium elevation in the overall cohort between two groups.
Measured by blood electrolytes
Time frame: At baseline and 2 month of follow-up
Compare the change of daytime mean diastolic blood pressure in the overall cohort between two groups.
Measured by ambulatory blood pressure monitoring
Time frame: At baseline and 2 month of follow-up
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chongqing Medical University